David-Alexandre C. Gros

SVP, Chief Business Officer, Alnylam Pharmaceuticals.

Companies

Eledon Pharmaceuticals, Inc.Board member Sep 15, 2020 to now¹
Eledon Pharmaceuticals, Inc.Chief executive officer Sep 15, 2020 to now¹
Neurocrine BiosciencesChief operating officer Jan 9, 2017 to Feb 8, 2017²
Neurocrine BiosciencesPresident Jan 9, 2017 to Feb 8, 2017²
Alnylam PharmaceuticalsSVP, Chief Business Officer Jun 10, 2015 to Dec 22, 2016³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Eledon Pharmaceuticals, Inc. ELDN168,663 shares⁴$371.9K at $2.21Jul 31, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

Jul 31, 2026Shares withheld for tax 194,791 shares at $3.38 of Eledon Pharmaceuticals, Inc.⁴
Jul 31, 2026Granted 354,454 shares of Eledon Pharmaceuticals, Inc.⁴
Dec 20, 2021Bought 2,000 shares at $4.48 of Eledon Pharmaceuticals, Inc.⁵

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREledon Pharmaceuticals, Inc., Board member
2
SEC EDGARNeurocrine Biosciences, Chief operating officer
3
SEC EDGARAlnylam Pharmaceuticals, SVP, Chief Business Officer
4
SEC EDGAREledon Pharmaceuticals, Inc. shares after the filing of Jul 31, 2026
5
SEC EDGARForm 4 filed Dec 21, 2021